159 related articles for article (PubMed ID: 38467922)
21. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
22. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract][Full Text] [Related]
23. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
24. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
25. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
26. Extended therapy with [
Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
[TBL] [Abstract][Full Text] [Related]
27. [
Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
[TBL] [Abstract][Full Text] [Related]
28.
Satapathy S; Mittal BR; Sood A; Das CK; Mavuduru RS; Goyal S; Shukla J; Singh SK
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1754-1764. PubMed ID: 34842950
[TBL] [Abstract][Full Text] [Related]
29. The
Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
[TBL] [Abstract][Full Text] [Related]
30. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
31. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
Flippot R; Telli T; Velev M; Fléchon A; De Vries-Brilland M; Turpin L; Bergman A; Turco F; Mahammedi H; Fendler WP; Giraudet AL; Josset Q; Montravers F; Vogel W; Gillessen S; Berardi Vilei S; Herrmann K; Kryza D; Paone G; Hadaschik B; Merlin C; Dufour PA; Bernard-Tessier A; Naoun N; Patrikidou A; Garcia C; Foulon S; Pagès A; Fizazi K
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38664139
[TBL] [Abstract][Full Text] [Related]
32. RECIP 1.0 Predicts Progression-Free Survival After [
Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M
J Nucl Med; 2024 Jun; 65(6):917-922. PubMed ID: 38637143
[TBL] [Abstract][Full Text] [Related]
33.
Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
[TBL] [Abstract][Full Text] [Related]
34. Promising Therapeutic Activity of 177 Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer : A Pilot Experience.
Satapathy S; Yadav MP; Ballal S; Sahoo RK; Bal C
Clin Nucl Med; 2024 Feb; 49(2):131-137. PubMed ID: 38049970
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
36. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract][Full Text] [Related]
37. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
38. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
39. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
40. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
Almuradova E; Seyyar M; Arak H; Tamer F; Kefeli U; Koca S; Sen E; Telli TA; Karatas F; Gokmen I; Turhal NS; Sakalar T; Ayhan M; Ekinci F; Hafizoglu E; Kahraman S; Kesen O; Unal C; Alan O; Celik S; Yekeduz E; Omur O; Gokmen E
Int J Cancer; 2024 Feb; 154(4):692-700. PubMed ID: 37818966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]